Loading...

PE anti-mouse NK-1.1 Antibody PE anti-mouse NK-1.1 Antibody

Pricing & Availability
Clone
PK136 (See other available formats)
Regulatory Status
RUO
Other Names
NKR-P1C, NKR-P1B, Ly-55, CD161, CD161b, CD161c
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
PK136_PE_NK-11_Antibody_051018
C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and NK1.1 (clone PK136) PE (left) or mouse IgG2a, κ PE isotype control (right).
  • PK136_PE_NK-11_Antibody_051018
    C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and NK1.1 (clone PK136) PE (left) or mouse IgG2a, κ PE isotype control (right).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
108707 50 µg DKK363
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108708 200 µg DKK1064
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NK-1+ cells from mouse spleen and bone marrow
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, complement-dependent cytotoxicity3, in vivo depletion4,5,9,10, mediation of in vitro redirected lysis6, blocking of NK cell function7, induction of proliferation8, immunohistochemical staining of frozen sections11, immunofluorescence microscopy11, and spatial biology (IBEX)16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Application References
  1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
  2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
  3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
  4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
  5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
  6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
  8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
  9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
  11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
  12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
  13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
  14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sade-Feldman M,et al. 2017. Nat Commun.. 10.1038/s41467-017-01062-w. PubMed
  2. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  3. Hiyoshi H, et al. 2022. Cell Host Microbe. 30:163. PubMed
  4. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  5. West HC, et al. 2022. Cell Rep. 39:110819. PubMed
  6. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  7. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  8. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  9. Kaltenbach L, et al. 2023. Nat Immunol. 24:915. PubMed
  10. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  11. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  12. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  13. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  14. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  15. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  16. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  17. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  18. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  19. Lee Y, et al. 2020. J Innate Immun. 1:. PubMed
  20. Israelow B, et al. 2020. bioRxiv. . PubMed
  21. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  22. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  23. Zheng M, et al. 2016. Sci Rep. 6:28729. PubMed
  24. Engel O, et al. 2015. Stroke. 46: 3232 - 3240. PubMed
  25. Valencia–Hernandez AM, et al. 2020. Cell Host & Microbe. 27(6):950-962. PubMed
  26. John S, et al. 2020. Sci Rep. 10:11377. PubMed
  27. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  28. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  29. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  30. Adomati T, et al. 2020. Cell Reports. 30(11):3671-3681. PubMed
  31. Hsieh M, et al. 2006. J Immunol. 177:1855. PubMed
  32. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  33. Böttcher JP, et al. 2018. Cell. 172:1022. PubMed
  34. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  35. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  36. Liu X, et al. 2020. Nature. . PubMed
  37. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  38. Lee AK, et al. 2020. Radiat Res. 193:305. PubMed
  39. Nakagawa S et al. 2017. Cell host & microbe. 22(5):667-677 . PubMed
  40. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  41. Shemer A, et al. 2020. Immunity. 53(5):1033-1049.e7. PubMed
  42. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  43. Shibata K, et al. 2014. J Immunol. 192:2210. PubMed
  44. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  45. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  46. Astrakhan A, et al. 2009. J Immunol. 182:7370. PubMed
  47. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  48. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  49. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
  50. Marsh S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1316 - 1325. PubMed
  51. Spees A, et al. 2014. Infect Immun . 82:1692. PubMed
  52. Chen Y, et al. 2012. PLoS One. 7:e47190. PubMed
  53. Li J, et al. 2019. JCI Insight. 5. PubMed
  54. Martens CR, et al. 2022. PLoS Pathog. 18:e1010342. PubMed
  55. Zhou Y, et al. 2022. Nat Commun. 13:2906. PubMed
  56. Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed
  57. Lee M, et al. 2014. PLoS One. 9:112666. PubMed
  58. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  59. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  60. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  61. Ruf B, et al. 2021. Cancer Immunol Res. 9:1024. PubMed
  62. McAlpine CS, et al. 2021. Nature. 595:701. PubMed
  63. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  64. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  65. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  66. Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
  67. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  68. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  69. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  70. Galvani E, et al. 2020. Nat Commun. 11:853. PubMed
  71. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  72. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  73. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  74. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  75. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  76. Markman JL, et al. 2020. Nat Commun. 11:1613. PubMed
  77. Kim DH, et al. 2018. Nat Commun. 9:503. PubMed
  78. Li Z, et al. 2018. Front Immunol. 9:347. PubMed
  79. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  80. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  81. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  82. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  83. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  84. Olson M, et al. 2014. J Immunol. 193:5420. PubMed
  85. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  86. Duan B, et al. 2010. J Immunol. 185:335. PubMed
  87. Kadowaki T, et al. 2012. Clin Immunol. 142:296. PubMed
  88. Bachu M, et al. 2019. J Biol Chem. 294:1904. PubMed
  89. Wu S, et al. 2022. BMC Immunol. 23:17. PubMed
  90. Lang V, et al. 2021. Elife. 10:. PubMed
  91. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  92. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  93. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  94. Korrer M, Routes J 2014. PLoS One. 9:91370. PubMed
  95. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  96. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  97. Gamrekelashvili J, et al. 2021. Bio Protoc. 11:e4007. PubMed
  98. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  99. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  100. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  101. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  102. Yang C, et al. 2016. Sci Rep. 6:34643. PubMed
  103. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  104. Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed
  105. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  106. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  107. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  108. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
  109. Lokken K, et al. 2014. PLoS Pathog. 10:1004049. PubMed
  110. Hohsfield LA, et al. 2020. J Neuroinflammation. 0.902083333. PubMed
  111. Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed
  112. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  113. Okamoto T, et al. 2011. Biomaterials. 32:4925. PubMed
  114. Kitur K, et al. 2015. PLoS Pathog. 11:1004820. PubMed
  115. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  116. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  117. He B, et al. 2020. Cell Reports. 30(3):714-724.e5.. PubMed
  118. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  119. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  120. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  121. Rustenhoven J, et al. 2021. Cell. 184(4):1000-1016.e27. PubMed
  122. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  123. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  124. Salazar V, et al. 2019. Cell Rep. 26:1585. PubMed
  125. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  126. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  127. Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed
  128. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  129. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  130. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  131. Orr MT, et al. 2019. NPJ Vaccines. 4:1. PubMed
  132. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
  133. Zhou X, et al. 2021. Nutr Metab (Lond). 18:64. PubMed
  134. Wu C, et al. 2018. Scand J Immunol. 87:e12661. PubMed
  135. Hohsfield LA, et al. 2021. Elife. 10:. PubMed
  136. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  137. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  138. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  139. Dienz O, et al. 2009. J Exp Med. 206:69. PubMed
  140. Sade-Feldman M,et al. 2017. Nat Commun.. 10.1038/s41467-017-01062-w. PubMed
  141. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  142. Hiyoshi H, et al. 2022. Cell Host Microbe. 30:163. PubMed
  143. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  144. West HC, et al. 2022. Cell Rep. 39:110819. PubMed
  145. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  146. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  147. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  148. Kaltenbach L, et al. 2023. Nat Immunol. 24:915. PubMed
  149. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  150. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  151. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  152. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  153. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  154. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  155. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  156. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  157. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  158. Lee Y, et al. 2020. J Innate Immun. 1:. PubMed
  159. Israelow B, et al. 2020. bioRxiv. . PubMed
  160. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  161. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  162. Zheng M, et al. 2016. Sci Rep. 6:28729. PubMed
  163. Engel O, et al. 2015. Stroke. 46: 3232 - 3240. PubMed
  164. Valencia–Hernandez AM, et al. 2020. Cell Host & Microbe. 27(6):950-962. PubMed
  165. John S, et al. 2020. Sci Rep. 10:11377. PubMed
  166. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  167. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  168. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  169. Adomati T, et al. 2020. Cell Reports. 30(11):3671-3681. PubMed
  170. Hsieh M, et al. 2006. J Immunol. 177:1855. PubMed
  171. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  172. Böttcher JP, et al. 2018. Cell. 172:1022. PubMed
  173. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  174. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  175. Liu X, et al. 2020. Nature. . PubMed
  176. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  177. Lee AK, et al. 2020. Radiat Res. 193:305. PubMed
  178. Nakagawa S et al. 2017. Cell host & microbe. 22(5):667-677 . PubMed
  179. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  180. Shemer A, et al. 2020. Immunity. 53(5):1033-1049.e7. PubMed
  181. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  182. Shibata K, et al. 2014. J Immunol. 192:2210. PubMed
  183. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  184. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  185. Astrakhan A, et al. 2009. J Immunol. 182:7370. PubMed
  186. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  187. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  188. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
  189. Marsh S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1316 - 1325. PubMed
  190. Spees A, et al. 2014. Infect Immun . 82:1692. PubMed
  191. Chen Y, et al. 2012. PLoS One. 7:e47190. PubMed
  192. Li J, et al. 2019. JCI Insight. 5. PubMed
  193. Martens CR, et al. 2022. PLoS Pathog. 18:e1010342. PubMed
  194. Zhou Y, et al. 2022. Nat Commun. 13:2906. PubMed
  195. Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed
  196. Lee M, et al. 2014. PLoS One. 9:112666. PubMed
  197. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  198. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  199. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  200. Ruf B, et al. 2021. Cancer Immunol Res. 9:1024. PubMed
  201. McAlpine CS, et al. 2021. Nature. 595:701. PubMed
  202. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  203. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  204. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  205. Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
  206. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  207. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  208. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  209. Galvani E, et al. 2020. Nat Commun. 11:853. PubMed
  210. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  211. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  212. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  213. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  214. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  215. Markman JL, et al. 2020. Nat Commun. 11:1613. PubMed
  216. Kim DH, et al. 2018. Nat Commun. 9:503. PubMed
  217. Li Z, et al. 2018. Front Immunol. 9:347. PubMed
  218. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  219. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  220. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  221. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  222. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  223. Olson M, et al. 2014. J Immunol. 193:5420. PubMed
  224. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  225. Duan B, et al. 2010. J Immunol. 185:335. PubMed
  226. Kadowaki T, et al. 2012. Clin Immunol. 142:296. PubMed
  227. Bachu M, et al. 2019. J Biol Chem. 294:1904. PubMed
  228. Wu S, et al. 2022. BMC Immunol. 23:17. PubMed
  229. Lang V, et al. 2021. Elife. 10:. PubMed
  230. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  231. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  232. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  233. Korrer M, Routes J 2014. PLoS One. 9:91370. PubMed
  234. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  235. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  236. Gamrekelashvili J, et al. 2021. Bio Protoc. 11:e4007. PubMed
  237. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  238. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  239. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  240. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  241. Yang C, et al. 2016. Sci Rep. 6:34643. PubMed
  242. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  243. Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed
  244. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  245. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  246. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  247. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
  248. Lokken K, et al. 2014. PLoS Pathog. 10:1004049. PubMed
  249. Hohsfield LA, et al. 2020. J Neuroinflammation. 0.902083333. PubMed
  250. Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed
  251. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  252. Okamoto T, et al. 2011. Biomaterials. 32:4925. PubMed
  253. Kitur K, et al. 2015. PLoS Pathog. 11:1004820. PubMed
  254. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  255. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  256. He B, et al. 2020. Cell Reports. 30(3):714-724.e5.. PubMed
  257. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  258. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  259. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  260. Rustenhoven J, et al. 2021. Cell. 184(4):1000-1016.e27. PubMed
  261. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  262. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  263. Salazar V, et al. 2019. Cell Rep. 26:1585. PubMed
  264. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  265. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  266. Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed
  267. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  268. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  269. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  270. Orr MT, et al. 2019. NPJ Vaccines. 4:1. PubMed
  271. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
  272. Zhou X, et al. 2021. Nutr Metab (Lond). 18:64. PubMed
  273. Wu C, et al. 2018. Scand J Immunol. 87:e12661. PubMed
  274. Hohsfield LA, et al. 2021. Elife. 10:. PubMed
  275. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  276. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  277. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  278. Dienz O, et al. 2009. J Exp Med. 206:69. PubMed
RRID
AB_313394 (BioLegend Cat. No. 108707)
AB_313395 (BioLegend Cat. No. 108708)

Antigen Details

Structure
NKR-P1 gene family
Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function
NK cell activation, IFN-γ production, cytotoxic granule release
Cell Type
NK cells, NKT cells
Biology Area
Immunology, Innate Immunity
Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID
17059 View all products for this Gene ID
UniProt
View information about NK-1.1 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All NK-1.1 Reagents Request Custom Conjugation
Description Clone Applications
PE/Dazzle™ 594 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 785™ anti-mouse NK-1.1 PK136 FC
APC/Fire™ 750 anti-mouse NK-1.1 PK136 FC
TotalSeq™-A0118 anti-mouse NK-1.1 PK136 PG
Ultra-LEAF™ Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
TotalSeq™-C0118 anti-mouse NK-1.1 PK136 PG
TotalSeq™-B0118 anti-mouse NK-1.1 PK136 PG
APC anti-mouse NK-1.1 PK136 FC
Biotin anti-mouse NK-1.1 PK136 FC
FITC anti-mouse NK-1.1 PK136 FC
PE anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
PE/Cyanine7 anti-mouse NK-1.1 PK136 FC
PE/Cyanine5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 488 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 647 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 711™ anti-mouse NK-1.1 PK136 FC
Pacific Blue™ anti-mouse NK-1.1 PK136 FC
APC/Cyanine7 anti-mouse NK-1.1 PK136 FC
PerCP anti-mouse NK-1.1 PK136 FC
PerCP/Cyanine5.5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 700 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 421™ anti-mouse NK-1.1 PK136 FC,SB
Brilliant Violet 570™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 650™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 510™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 605™ anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 (Maxpar® Ready) PK136 FC,CyTOF®
PE/Fire™ 640 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 810 anti-mouse NK-1.1 PK136 FC
Spark UV™ 387 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 700 anti-mouse NK-1.1 PK136 FC
Spark YG™ 593 anti-mouse NK-1.1 (Flexi-Fluor™) Antibody PK136 FC
Go To Top Version: 3    Revision Date: 05/10/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
PK136 (See other available formats)
Regulatory Status
RUO
Other Names
NKR-P1C, NKR-P1B, Ly-55, CD161, CD161b, CD161c
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
PK136_PE_NK-11_Antibody_051018
C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and NK1.1 (clone PK136) PE (left) or mouse IgG2a, κ PE isotype control (right).
  • PK136_PE_NK-11_Antibody_051018
    C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and NK1.1 (clone PK136) PE (left) or mouse IgG2a, κ PE isotype control (right).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
108707 50 µg DKK363
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108708 200 µg DKK1064
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NK-1+ cells from mouse spleen and bone marrow
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, complement-dependent cytotoxicity3, in vivo depletion4,5,9,10, mediation of in vitro redirected lysis6, blocking of NK cell function7, induction of proliferation8, immunohistochemical staining of frozen sections11, immunofluorescence microscopy11, and spatial biology (IBEX)16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Application References
  1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
  2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
  3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
  4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
  5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
  6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
  8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
  9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
  11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
  12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
  13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
  14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sade-Feldman M,et al. 2017. Nat Commun.. 10.1038/s41467-017-01062-w. PubMed
  2. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  3. Hiyoshi H, et al. 2022. Cell Host Microbe. 30:163. PubMed
  4. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  5. West HC, et al. 2022. Cell Rep. 39:110819. PubMed
  6. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  7. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  8. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  9. Kaltenbach L, et al. 2023. Nat Immunol. 24:915. PubMed
  10. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  11. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  12. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  13. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  14. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  15. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  16. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  17. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  18. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  19. Lee Y, et al. 2020. J Innate Immun. 1:. PubMed
  20. Israelow B, et al. 2020. bioRxiv. . PubMed
  21. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  22. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  23. Zheng M, et al. 2016. Sci Rep. 6:28729. PubMed
  24. Engel O, et al. 2015. Stroke. 46: 3232 - 3240. PubMed
  25. Valencia–Hernandez AM, et al. 2020. Cell Host & Microbe. 27(6):950-962. PubMed
  26. John S, et al. 2020. Sci Rep. 10:11377. PubMed
  27. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  28. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  29. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  30. Adomati T, et al. 2020. Cell Reports. 30(11):3671-3681. PubMed
  31. Hsieh M, et al. 2006. J Immunol. 177:1855. PubMed
  32. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  33. Böttcher JP, et al. 2018. Cell. 172:1022. PubMed
  34. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  35. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  36. Liu X, et al. 2020. Nature. . PubMed
  37. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  38. Lee AK, et al. 2020. Radiat Res. 193:305. PubMed
  39. Nakagawa S et al. 2017. Cell host & microbe. 22(5):667-677 . PubMed
  40. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  41. Shemer A, et al. 2020. Immunity. 53(5):1033-1049.e7. PubMed
  42. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  43. Shibata K, et al. 2014. J Immunol. 192:2210. PubMed
  44. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  45. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  46. Astrakhan A, et al. 2009. J Immunol. 182:7370. PubMed
  47. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  48. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  49. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
  50. Marsh S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1316 - 1325. PubMed
  51. Spees A, et al. 2014. Infect Immun . 82:1692. PubMed
  52. Chen Y, et al. 2012. PLoS One. 7:e47190. PubMed
  53. Li J, et al. 2019. JCI Insight. 5. PubMed
  54. Martens CR, et al. 2022. PLoS Pathog. 18:e1010342. PubMed
  55. Zhou Y, et al. 2022. Nat Commun. 13:2906. PubMed
  56. Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed
  57. Lee M, et al. 2014. PLoS One. 9:112666. PubMed
  58. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  59. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  60. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  61. Ruf B, et al. 2021. Cancer Immunol Res. 9:1024. PubMed
  62. McAlpine CS, et al. 2021. Nature. 595:701. PubMed
  63. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  64. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  65. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  66. Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
  67. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  68. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  69. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  70. Galvani E, et al. 2020. Nat Commun. 11:853. PubMed
  71. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  72. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  73. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  74. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  75. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  76. Markman JL, et al. 2020. Nat Commun. 11:1613. PubMed
  77. Kim DH, et al. 2018. Nat Commun. 9:503. PubMed
  78. Li Z, et al. 2018. Front Immunol. 9:347. PubMed
  79. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  80. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  81. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  82. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  83. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  84. Olson M, et al. 2014. J Immunol. 193:5420. PubMed
  85. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  86. Duan B, et al. 2010. J Immunol. 185:335. PubMed
  87. Kadowaki T, et al. 2012. Clin Immunol. 142:296. PubMed
  88. Bachu M, et al. 2019. J Biol Chem. 294:1904. PubMed
  89. Wu S, et al. 2022. BMC Immunol. 23:17. PubMed
  90. Lang V, et al. 2021. Elife. 10:. PubMed
  91. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  92. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  93. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  94. Korrer M, Routes J 2014. PLoS One. 9:91370. PubMed
  95. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  96. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  97. Gamrekelashvili J, et al. 2021. Bio Protoc. 11:e4007. PubMed
  98. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  99. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  100. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  101. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  102. Yang C, et al. 2016. Sci Rep. 6:34643. PubMed
  103. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  104. Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed
  105. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  106. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  107. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  108. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
  109. Lokken K, et al. 2014. PLoS Pathog. 10:1004049. PubMed
  110. Hohsfield LA, et al. 2020. J Neuroinflammation. 0.902083333. PubMed
  111. Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed
  112. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  113. Okamoto T, et al. 2011. Biomaterials. 32:4925. PubMed
  114. Kitur K, et al. 2015. PLoS Pathog. 11:1004820. PubMed
  115. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  116. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  117. He B, et al. 2020. Cell Reports. 30(3):714-724.e5.. PubMed
  118. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  119. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  120. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  121. Rustenhoven J, et al. 2021. Cell. 184(4):1000-1016.e27. PubMed
  122. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  123. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  124. Salazar V, et al. 2019. Cell Rep. 26:1585. PubMed
  125. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  126. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  127. Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed
  128. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  129. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  130. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  131. Orr MT, et al. 2019. NPJ Vaccines. 4:1. PubMed
  132. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
  133. Zhou X, et al. 2021. Nutr Metab (Lond). 18:64. PubMed
  134. Wu C, et al. 2018. Scand J Immunol. 87:e12661. PubMed
  135. Hohsfield LA, et al. 2021. Elife. 10:. PubMed
  136. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  137. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  138. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  139. Dienz O, et al. 2009. J Exp Med. 206:69. PubMed
  140. Sade-Feldman M,et al. 2017. Nat Commun.. 10.1038/s41467-017-01062-w. PubMed
  141. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  142. Hiyoshi H, et al. 2022. Cell Host Microbe. 30:163. PubMed
  143. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  144. West HC, et al. 2022. Cell Rep. 39:110819. PubMed
  145. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  146. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  147. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  148. Kaltenbach L, et al. 2023. Nat Immunol. 24:915. PubMed
  149. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  150. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  151. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  152. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  153. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  154. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  155. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  156. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  157. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  158. Lee Y, et al. 2020. J Innate Immun. 1:. PubMed
  159. Israelow B, et al. 2020. bioRxiv. . PubMed
  160. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  161. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  162. Zheng M, et al. 2016. Sci Rep. 6:28729. PubMed
  163. Engel O, et al. 2015. Stroke. 46: 3232 - 3240. PubMed
  164. Valencia–Hernandez AM, et al. 2020. Cell Host & Microbe. 27(6):950-962. PubMed
  165. John S, et al. 2020. Sci Rep. 10:11377. PubMed
  166. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  167. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  168. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  169. Adomati T, et al. 2020. Cell Reports. 30(11):3671-3681. PubMed
  170. Hsieh M, et al. 2006. J Immunol. 177:1855. PubMed
  171. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  172. Böttcher JP, et al. 2018. Cell. 172:1022. PubMed
  173. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  174. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  175. Liu X, et al. 2020. Nature. . PubMed
  176. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  177. Lee AK, et al. 2020. Radiat Res. 193:305. PubMed
  178. Nakagawa S et al. 2017. Cell host & microbe. 22(5):667-677 . PubMed
  179. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  180. Shemer A, et al. 2020. Immunity. 53(5):1033-1049.e7. PubMed
  181. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  182. Shibata K, et al. 2014. J Immunol. 192:2210. PubMed
  183. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  184. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  185. Astrakhan A, et al. 2009. J Immunol. 182:7370. PubMed
  186. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  187. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  188. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
  189. Marsh S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1316 - 1325. PubMed
  190. Spees A, et al. 2014. Infect Immun . 82:1692. PubMed
  191. Chen Y, et al. 2012. PLoS One. 7:e47190. PubMed
  192. Li J, et al. 2019. JCI Insight. 5. PubMed
  193. Martens CR, et al. 2022. PLoS Pathog. 18:e1010342. PubMed
  194. Zhou Y, et al. 2022. Nat Commun. 13:2906. PubMed
  195. Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed
  196. Lee M, et al. 2014. PLoS One. 9:112666. PubMed
  197. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  198. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  199. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  200. Ruf B, et al. 2021. Cancer Immunol Res. 9:1024. PubMed
  201. McAlpine CS, et al. 2021. Nature. 595:701. PubMed
  202. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  203. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  204. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  205. Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
  206. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  207. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  208. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  209. Galvani E, et al. 2020. Nat Commun. 11:853. PubMed
  210. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  211. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  212. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  213. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  214. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  215. Markman JL, et al. 2020. Nat Commun. 11:1613. PubMed
  216. Kim DH, et al. 2018. Nat Commun. 9:503. PubMed
  217. Li Z, et al. 2018. Front Immunol. 9:347. PubMed
  218. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  219. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  220. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  221. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  222. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  223. Olson M, et al. 2014. J Immunol. 193:5420. PubMed
  224. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  225. Duan B, et al. 2010. J Immunol. 185:335. PubMed
  226. Kadowaki T, et al. 2012. Clin Immunol. 142:296. PubMed
  227. Bachu M, et al. 2019. J Biol Chem. 294:1904. PubMed
  228. Wu S, et al. 2022. BMC Immunol. 23:17. PubMed
  229. Lang V, et al. 2021. Elife. 10:. PubMed
  230. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  231. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  232. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  233. Korrer M, Routes J 2014. PLoS One. 9:91370. PubMed
  234. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  235. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  236. Gamrekelashvili J, et al. 2021. Bio Protoc. 11:e4007. PubMed
  237. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  238. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  239. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  240. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  241. Yang C, et al. 2016. Sci Rep. 6:34643. PubMed
  242. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  243. Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed
  244. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  245. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  246. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  247. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
  248. Lokken K, et al. 2014. PLoS Pathog. 10:1004049. PubMed
  249. Hohsfield LA, et al. 2020. J Neuroinflammation. 0.902083333. PubMed
  250. Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed
  251. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  252. Okamoto T, et al. 2011. Biomaterials. 32:4925. PubMed
  253. Kitur K, et al. 2015. PLoS Pathog. 11:1004820. PubMed
  254. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  255. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  256. He B, et al. 2020. Cell Reports. 30(3):714-724.e5.. PubMed
  257. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  258. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  259. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  260. Rustenhoven J, et al. 2021. Cell. 184(4):1000-1016.e27. PubMed
  261. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  262. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  263. Salazar V, et al. 2019. Cell Rep. 26:1585. PubMed
  264. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  265. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  266. Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed
  267. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  268. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  269. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  270. Orr MT, et al. 2019. NPJ Vaccines. 4:1. PubMed
  271. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
  272. Zhou X, et al. 2021. Nutr Metab (Lond). 18:64. PubMed
  273. Wu C, et al. 2018. Scand J Immunol. 87:e12661. PubMed
  274. Hohsfield LA, et al. 2021. Elife. 10:. PubMed
  275. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  276. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  277. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  278. Dienz O, et al. 2009. J Exp Med. 206:69. PubMed
RRID
AB_313394 (BioLegend Cat. No. 108707)
AB_313395 (BioLegend Cat. No. 108708)

Antigen Details

Structure
NKR-P1 gene family
Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function
NK cell activation, IFN-γ production, cytotoxic granule release
Cell Type
NK cells, NKT cells
Biology Area
Immunology, Innate Immunity
Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID
17059 View all products for this Gene ID
UniProt
View information about NK-1.1 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All NK-1.1 Reagents Request Custom Conjugation
Description Clone Applications
PE/Dazzle™ 594 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 785™ anti-mouse NK-1.1 PK136 FC
APC/Fire™ 750 anti-mouse NK-1.1 PK136 FC
TotalSeq™-A0118 anti-mouse NK-1.1 PK136 PG
Ultra-LEAF™ Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
TotalSeq™-C0118 anti-mouse NK-1.1 PK136 PG
TotalSeq™-B0118 anti-mouse NK-1.1 PK136 PG
APC anti-mouse NK-1.1 PK136 FC
Biotin anti-mouse NK-1.1 PK136 FC
FITC anti-mouse NK-1.1 PK136 FC
PE anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
PE/Cyanine7 anti-mouse NK-1.1 PK136 FC
PE/Cyanine5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 488 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 647 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 711™ anti-mouse NK-1.1 PK136 FC
Pacific Blue™ anti-mouse NK-1.1 PK136 FC
APC/Cyanine7 anti-mouse NK-1.1 PK136 FC
PerCP anti-mouse NK-1.1 PK136 FC
PerCP/Cyanine5.5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 700 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 421™ anti-mouse NK-1.1 PK136 FC,SB
Brilliant Violet 570™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 650™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 510™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 605™ anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 (Maxpar® Ready) PK136 FC,CyTOF®
PE/Fire™ 640 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 810 anti-mouse NK-1.1 PK136 FC
Spark UV™ 387 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 700 anti-mouse NK-1.1 PK136 FC
Spark YG™ 593 anti-mouse NK-1.1 (Flexi-Fluor™) Antibody PK136 FC
Go To Top Version: 3    Revision Date: 05/10/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account